Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Monday, February 2, 2026 1 min read
Key Takeaway: Opus Genetics, a clinical-stage biopharmaceutical company, announced its participation in several prominent ophthalmology and industry conferences in February 2026. These events include the Collaborative Community on Ophthalmic Innovation, the Asia-Pacific Academy of Ophthalmology Congress, and the Advanced Therapies Week Conference. The company is focused on developing gene therapies aimed at restoring vision in patients with inherited retinal diseases.
Price reaction · baseline $2.31 (2026-01-30 close) · hit pre-market · clean, no other IRD news in the window
day 0 close
+0.4%
Market Sentiment Analysis
POSITIVE FACTORS
Opus Genetics is actively participating in key industry conferences.
The company is focused on developing innovative gene therapies.
Their pipeline includes multiple promising gene therapy candidates.
The leadership team's engagement in conferences highlights their commitment to the field.
Full Press Release Details
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) --Opus Genetics,Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences.
Collaborative Community on Ophthalmic Innovation (CCOI)
Asia-Pacific Academy of Ophthalmology Congress (APAO)
Advanced Therapies Week Conference
The Macula Society Annual Meeting
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visitwww.opusgtx.com.
What conferences will Opus Genetics attend in February 2026?
Opus Genetics will attend the Collaborative Community on Ophthalmic Innovation, Asia-Pacific Academy of Ophthalmology Congress, and Advanced Therapies Week Conference.
What is the focus of Opus Genetics?
Opus Genetics focuses on developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases.
What is included in Opus Genetics' pipeline?
Their pipeline includes seven AAV-based programs targeting various genetic mutations related to retinal disorders.
Where is Opus Genetics based?
Opus Genetics is based in Research Triangle Park, North Carolina.